Research graph
References from Tarlatamab in Relapsed SCLC With Idiopathic Pulmonary Fibrosis: A Case With Comparative DLL3 Expression Analysis: Case Report. Local targets link to admitted publications; unresolved targets remain external evidence.
Tarlatamab for patients with previously treated small-cell lung cancer
10.1056/nejmoa2307980 · 2023 · External reference
Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema
10.1016/j.lungcan.2014.05.016 · 2014 · External reference
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
10.1038/s41698-024-00739-y · 2024 · External reference
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
10.1126/scitranslmed.aac9459 · 2015 · External reference
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
10.1016/j.ccell.2021.09.008 · 2021 · External reference
Signatures of plasticity, metastasis, and immunosuppression in an atlas of human small cell lung cancer
10.1016/j.ccell.2021.09.008 · ExternalCitation · doi-reference
Clinical features, anti-cancer treatments and outcomes of lung cancer patients with combined pulmonary fibrosis and emphysema
10.1016/j.lungcan.2014.05.016 · ExternalCitation · doi-reference
Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms
10.1038/s41698-024-00739-y · ExternalCitation · doi-reference
Tarlatamab for patients with previously treated small-cell lung cancer
10.1056/nejmoa2307980 · ExternalCitation · doi-reference
A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo
10.1126/scitranslmed.aac9459 · ExternalCitation · doi-reference
